Nektar Therapeutics
NASDAQ:NKTR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.42
1.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Nektar Therapeutics
Nektar Therapeutics
Cash from Operating Activities
Nektar Therapeutics
Cash from Operating Activities Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Cash from Operating Activities
-$174.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-17%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$25.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$15B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$18.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
See Also
What is Nektar Therapeutics's Cash from Operating Activities?
Cash from Operating Activities
-174.8m
USD
Based on the financial report for Jun 30, 2024, Nektar Therapeutics's Cash from Operating Activities amounts to -174.8m USD.
What is Nektar Therapeutics's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-17%
Over the last year, the Cash from Operating Activities growth was 28%. The average annual Cash from Operating Activities growth rates for Nektar Therapeutics have been 18% over the past three years , 12% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet
